Lupin has signed an agreement with GSK Philippines to manufacture and supply 4 & 2 fixed drug combinations (FDCs) of anti-TB drugs to GSK Philippines for marketing in Philippines. According to a release issued by Lupin to the BSE today, the FDCs are based on World Health Organisation (WHO) dosing guidelines."The arrangement seeks to leverage the intellectual property & technology of the company in the area of TB medication with the strong distribution and marketing infrastructure of GSK in the Philippines," the release added.
